These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 2965799)

  • 1. Immunogenicity of a recombinant yeast-derived hepatitis B vaccine (Engerix B) in children.
    Moyes C; Milne A
    N Z Med J; 1988 Apr; 101(843):162-4. PubMed ID: 2965799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety and immunogenicity of a recombinant hepatitis B vaccine in neonates.
    Gunn TR; Bosley A; Woodfield DG
    N Z Med J; 1989 Jan; 102(860):1-3. PubMed ID: 2521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of recombinant yeast-derived hepatitis B vaccine in haemodialysis patients.
    Fujiyama S; Yoshida K; Sato T; Shimada H; Deguchi T
    Hepatogastroenterology; 1990 Dec; 37 Suppl 2():140-4. PubMed ID: 2150664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody responses to recombinant, yeast-derived hepatitis B vaccine in teenage New Zealand children.
    Milne A; Moyes CD; Allwood GK; Pearce NE; Krugman S
    N Z Med J; 1988 Feb; 101(840):67-9. PubMed ID: 2967940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Reactivity and immunogenicity of Engerix B, the recombinant DNA vaccine against hepatitis B].
    Borcić B; Gasparović V; Mihaljevic I; Aleraj B; Margan IG
    Acta Med Iugosl; 1989; 43(4):247-54. PubMed ID: 2534021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of hepatitis B in children in a high risk New Zealand community, and control using recombinant DNA vaccine.
    Milne A; Heydon JL; Hindle RC; Pearce NE
    N Z Med J; 1989 Apr; 102(866):182-4. PubMed ID: 2523525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of a new mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in adults.
    Raz R; Koren R; Bass D
    Isr Med Assoc J; 2001 May; 3(5):328-32. PubMed ID: 11411195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of a yeast-derived hepatitis B vaccine (Engerix-B) in healthy young adults.
    Crovari P; Crovari PC; Petrilli RC; Icardi GC; Bonanni P
    Postgrad Med J; 1987; 63 Suppl 2():161-4. PubMed ID: 3317356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune response to hepatitis B vaccine in premature neonates.
    Chawareewong S; Jirapongsa A; Lokaphadhana K
    Southeast Asian J Trop Med Public Health; 1991 Mar; 22(1):39-40. PubMed ID: 1835140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evaluation of Engerix-B in healthy Malaysian medical students.
    Isahak I; Abdul Malik Y; Hakim AS; Baharin R
    Singapore Med J; 1990 Aug; 31(4):314-6. PubMed ID: 2147781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reactogenicity and immunogenicity of a recombinant hepatitis B vaccine compared with a plasma-derived vaccine in young adults.
    Just M; Berger R; Just V
    Postgrad Med J; 1987; 63 Suppl 2():121-3. PubMed ID: 3317346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents.
    Schiff GM; Sherwood JR; Zeldis JB; Krause DS
    J Adolesc Health; 1995 Jan; 16(1):12-7. PubMed ID: 7742331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune response to hepatitis B vaccine in infants and newborns: control trial in an endemic area (Senegal).
    Coursaget P; Deciron F; Tortey E; Barin F; Chiron JP; Yvonnet B; Diouf C; Denis F; Diop-Mar I; Correa P
    IARC Sci Publ; 1984; (63):319-35. PubMed ID: 6242150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination against hepatitis B virus in children and adolescents in a pediatric hospital.
    Catania G; Di Ciommo V; Concato C
    Recenti Prog Med; 1996 Jun; 87(6):271-4. PubMed ID: 8766952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity, reactogenicity and comparison of two doses of recombinant DNA yeast-derived hepatitis B vaccine in Ethiopian children.
    Tsega E; Tafesse B; Horton J; Nordenfelt E; Wolde-Hawariat G; Hansson BG; Lindberg J
    Trop Geogr Med; 1991; 43(1-2):220-7. PubMed ID: 1836290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy.
    Samandari T; Fiore AE; Negus S; Williams JL; Kuhnert W; McMahon BJ; Bell BP
    Pediatrics; 2007 Aug; 120(2):e373-81. PubMed ID: 17636112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low dose hepatitis B vaccination in children: benefit of low dose boosters.
    Milne A; Moyes CD; Dimitrakakis M
    N Z Med J; 1988 Jun; 101(847 Pt 1):370-1. PubMed ID: 2970604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of a new, low-cost recombinant hepatitis B vaccine derived from Hansenula polymorpha in adults.
    Kulkarni PS; Raut SK; Patki PS; Phadke MA; Jadhav SS; Kapre SV; Dhorje SP; Godse SR
    Vaccine; 2006 Apr; 24(17):3457-60. PubMed ID: 16530299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of two paediatric doses of monovalent hepatitis B or combined hepatitis A and B vaccine in 8-10-year-old children.
    Duval B; Gîlca V; Boulianne N; Deceuninck G; Rochette L; De Serres G
    Vaccine; 2005 Jul; 23(31):4082-7. PubMed ID: 15963363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immune response to hepatitis B vaccine produced with genetic engineering].
    Ramón Torrell JM; Micheo Salas C; Cerdó Goicouria C; Casas García I; Escribá Jordana JM
    Rev Clin Esp; 1991 Feb; 188(2):68-71. PubMed ID: 2041902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.